Back to top
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Image: Bigstock
Enzo Biochem (ENZ) Looks Good: Stock Adds 11% in Session
Enzo Biochem Inc. (ENZ - Free Report) was a big mover last session, as its shares rose a little more than 11% on the day. The move came after the company reported strong results for the fourth quarter and fiscal year ended July 31, 2016. This led to far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $4.92 to $5.48 in the past one-month time frame.
None of the estimates for this stock were revised over the past 30 days. The Zacks Consensus Estimate also remained unchanged over the same time frame. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Enzo Biochem currently carries a Zacks Rank #3 (Hold).
ENZO BIOCHEM Price
ENZO BIOCHEM Price | ENZO BIOCHEM Quote
A better-ranked stock in the med-biomed/gene space is Exelixis, Inc. (EXEL - Free Report) , which sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is ENZ going up? Or down? Predict to see what others think: Up or Down
Confidential from Zacks
Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>